MENU
+Compare
CDTX
Stock ticker: NASDAQ
AS OF
Jan 17, 04:59 PM (EDT)
Price
$21.77
Change
+$0.52 (+2.45%)
Capitalization
237.51M

CDTX Cidara Therapeutics Forecast, Technical & Fundamental Analysis

a developer of drugs for fungal infection

Industry Biotechnology
CDTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for CDTX with price predictions
Jan 08, 2025

CDTX sees MACD Histogram crosses below signal line

CDTX saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on January 08, 2025. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 52 instances where the indicator turned negative. In of the 52 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for CDTX moved out of overbought territory on January 08, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 49 cases where CDTX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

CDTX broke above its upper Bollinger Band on December 30, 2024. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on December 23, 2024. You may want to consider a long position or call options on CDTX as a result. In of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CDTX advanced for three days, in of 237 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 160 cases where CDTX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.054) is normal, around the industry mean (14.746). P/E Ratio (0.000) is within average values for comparable stocks, (88.252). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.853). CDTX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (2.451) is also within normal values, averaging (264.084).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CDTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CDTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
CDTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

a developer of drugs for fungal infection

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
6310 Nancy Ridge Drive
Phone
+1 858 752-6170
Employees
73
Web
https://www.cidara.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GLEAX14.700.09
+0.62%
GS Energy Infrastructure Fd A Shares
HFQDX6.140.03
+0.49%
Janus Henderson Global Equity Income D
NMVLX12.410.03
+0.24%
Nuance Mid Cap Value Institutional
MRJSX10.010.01
+0.10%
Morgan Stanley Multi-Asset Real ReturnR6
ALGAX18.86N/A
N/A
Alger International Opportunities A

CDTX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, CDTX has been closely correlated with BPTSY. These tickers have moved in lockstep 92% of the time. This A.I.-generated data suggests there is a high statistical probability that if CDTX jumps, then BPTSY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CDTX
1D Price
Change %
CDTX100%
+2.12%
BPTSY - CDTX
92%
Closely correlated
N/A
IVVD - CDTX
36%
Loosely correlated
-7.49%
CPRX - CDTX
35%
Loosely correlated
+0.53%
CABA - CDTX
33%
Poorly correlated
+12.76%
TRAW - CDTX
30%
Poorly correlated
-10.09%
More